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OBJECTIVES: The purpose of this study was to assess the direct
medical cost and indirect work-loss cost of bipolar disorder and
the comorbidities associated with this disease. METHODS: The
study sample was drawn from a de-identiﬁed administrative
claims database of approximately 1.8 million beneﬁciaries from
1999 to 2002, which included medical, drug, and disability
claims data. Patients between ages 18 and 65 years who had at
least 2 bipolar diagnoses, or 1 bipolar diagnosis and 1 prescrip-
tion for a mood stabilizer, were included in the bipolar sample
(N = 3499). A 1 :1 matching major depressive disorder (MDD)
control sample, and a 1 :1 matching nonbipolar/non-MDD
control sample with matching patient characteristics (age, sex,
employee status) were randomly selected. To assess excess annual
cost and comorbidities, we compared bipolar patients with the
matching samples. Cost analyses were conducted from an
employer’s perspective. All costs were adjusted to 2002 dollars
using Consumer Price Indices. T-tests or chi-square tests were
conducted to estimate statistical signiﬁcance. RESULTS: The
annual per patient medical cost of bipolar disorder was $7643;
the annual employee indirect cost was $2247. Compared with a
typical MDD patient, a bipolar patient experienced an incre-
mental health care cost of $1726 (P < 0.05), $741 (P < 0.05) for
drugs, $1237 (P < 0.05) for mental health services, $40 (P <
0.05) for emergency services, and $539 (P < 0.10) for employee
indirect work loss. Compared with nonbipolar/non-MDD
patients, bipolar patients had a higher risk of substance abuse
(relative risk [RR] = 11.6, P < 0.05), anxiety disorder (RR = 9.8,
P < 0.05), suicide/self-harm (RR = 26.0, P < 0.05), and
injury/accident (RR = 2.0, P < 0.05). The corresponding RRs for
comparisons with MDD patients were 6.4 (substance abuse), 
9.9 (anxiety disorder), 8.0 (suicide and self-harm), and 1.7
(injury/accident). CONCLUSIONS: Bipolar disorder is a costly
disease that is often associated with other mental conditions,
accidents, and suicide or self-harm.
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OBJECTIVES: While numerous studies have reported higher
prevalence of Type 2 diabetes mellitus in patients with bipolar
disorder, few have examined the impact of comorbid diabetes on
the costs associated with treating bipolar disorder patients in a
commercial health plan. This study explored differences in health
care costs between bipolar disorder patients with and without
comorbid diabetes. METHODS: Administrative claims data
from a large commercial health plan were used to identify preva-
lent bipolar disorder cases from medical claims based on a diag-
nosis code for bipolar disorder (ICD-9-CM diagnosis code
296.0x, 296.1x, 296.4x–296.7x) from 7/1/99 through 12/31/01.
Medical and pharmacy costs were calculated for a 365-day
period for continuously enrolled subjects. Costs were deﬁned as
bipolar-related if a bipolar diagnosis appeared in the primary
diagnosis position. Bipolar-related pharmacy costs were calcu-
lated from claims for mood stabilizers and atypical antipsy-
chotics. RESULTS: A total of 9459 bipolar disorder patients
were identiﬁed for analysis. Of these, 468 (5%) had a diabetes
diagnosis. Both median bipolar-related medical costs and median
pharmacy costs were lower for patients without diabetes com-
pared to patients with diabetes ($148 versus $205; $225 versus
$504). All-cause medical and pharmacy costs were also higher
among patients with comorbid diabetes. CONCLUSIONS:
Comorbid diabetes appears to substantially increase the cost of
providing both general medical care and bipolar-related health
services. Several mechanisms could account for these differences,
including clinical course of bipolar disorder, patient motivation
for medical care, and physician practice patterns. Further explo-
ration into these mechanisms is warranted.
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OBJECTIVES: The purpose of this study is to proﬁle the drug
treatment patterns of bipolar patients and compare the costs
associated with patients in alternative treatment groups.
METHODS: The study sample was drawn from a de-identiﬁed
administrative claims database of approximately 1.8 million
beneﬁciaries from 1999 to 2002, and including medical, drug,
and disability claims. Patients aged 18 to 65 years who had at
least 2 bipolar diagnoses, or 1 bipolar diagnosis and 1 prescrip-
tion for a mood stabilizer, were included (N = 3499). Costs were
measured from an employer’s perspective. All costs were adjusted
to 2002 dollars using Consumer Price Indices. T-tests were con-
ducted to estimate statistical signiﬁcance. RESULTS: Forty-ﬁve
percent of patients in the sample received no speciﬁc drug treat-
ment for bipolar disorder in the ﬁrst 2 months following their
diagnose, but 62% of this “no-treatment” group received anti-
depressants. Fifty percent of the sample took mood stabilizers in
the ﬁrst 2 months. Conventional antipsychotics were rarely used,
whereas atypical antipsychotics were usually taken concomi-
tantly with mood stabilizers. After the ﬁrst observed bipolar
episode, patients on mood stabilizer monotherapy incurred
increases in medical costs (36%) and drug costs (59%), and a
slight decrease in work-loss costs (-4.8%); patients on atypical
antipsychotics had a decrease in medical costs (16.8%), an
increase in drug costs (66%), and a decrease in work-loss costs
(13%). On average, therapy with atypical antipsychotics could
have saved $4796 annually, reﬂecting $4640 less in medical ser-
vices, $158 more in drug costs, and $314 less in indirect work-
loss costs compared with mood stabilizer monotherapy.
CONCLUSIONS: Bipolar patients were largely untreated or
treated inappropriately (with antidepressant monotherapy).
Appropriate combination therapy with atypical antipsychotics
and a mood stabilizer may reduce both direct health care costs
and indirect work-loss costs.
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OBJECTIVES: To assess the cost-effectiveness of olanzapine
compared with lithium in relapse prevention of bipolar I disor-
der. METHODS: Resource use data from a 52-week double-
blind randomised controlled trial of olanzapine versus lithium 
(n = 431) were used to determine costs of both treatments.
Resources considered were study drug, concomitant medication,
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hospitalisations and laboratory tests. This trial also reported rel-
ative safety and efﬁcacy. Australian cost data were applied to the
resource utilisation from the trial to estimate the overall treat-
ment costs associated with each therapy. Study drug and con-
comitant medication prices were sourced from the Schedule of
Pharmaceutical Beneﬁts and E-MIMS, while national casemix
costs were applied to hospitalisations. Rather than episodic
costing, a mixture of ﬁxed and marginal costs were used. Labo-
ratory test prices were from the Medicare Beneﬁts Schedule.
RESULTS: The overall cost of therapy for olanzapine patients
was AUS$9340 (US$6457), compared with A$9589 (US$6629)
for lithium patients. Although the acquisition cost of olanzapine
is greater than for lithium, the fewer (82 vs. 88) and shorter 
hospitalisations (15 vs. 19.7 days) associated with olanzapine
relative to lithium therapy lead to this overall cost saving of
AUS$249 (US$172). Olanzapine patients do not require labora-
tory tests to monitor serum lithium levels, which also contributes
to the cost saving. In terms of efﬁcacy, 8.8% (p = 0.055) fewer
olanzapine patients relapsed compared with lithium patients.
Additionally, 13.7% (p < 0.001) fewer olanzapine patients suf-
fered manic relapse. Time to relapse analysis conﬁrmed that ben-
eﬁts from olanzapine are maintained over a longer period than
those of lithium. Hence, the probability of relapse diverges over
time. When costs were varied in sensitivity analyses, olanzapine
continued to be cost-effective. CONCLUSIONS: Olanzapine dis-
plays greater efﬁcacy and is cost-saving compared to lithium.
Hence, olanzapine represents a dominant therapeutic option.
Sensitivity analysis indicated that even in extreme circumstances,
olanzapine remains cost-effective.
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OBJECTIVE: To examine mental health medical services uti-
lization and costs for patients in the depressive phase of bipolar.
METHODS: This retrospective study included a cohort of 1419
patients who had 3 consecutive years of data (majority between
1999 and 2001), received a diagnosis of bipolar depression (ICD
codes), and utilized one of three types of medical services; room
and board, medical/surgical, and ancillary services associated
with a mental disorder diagnosis. Medical service utilization and
costs were observed for a 1-year period post diagnosis index.
RESULTS: Twenty-one percent of patients incurred hospitaliza-
tion charges, averaged two admissions per year and accounted
for 50% of medical service costs. Average annual medical service
costs for patients who continue their initial treatment are $1950.
These cost more than triple ($6570) for patients who incur three
or more switches in a year. Additionally, the largest increase in
medical service costs is from the initial treatment ($1950) to the
ﬁrst switch ($3364). Bipolar depressed patients who received no
psychotropic medication incurred $3903 of medical service
costs. CONCLUSION: Patients with more “stabilized” treat-
ment had lower medical service costs than those patients who
experienced switches in pharmacologic treatment. Additionally,
non-medicated bipolar depressed patients incur high annual
costs to the managed care organization.
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OBJECTIVE: Prescribing patterns in bipolar disorder are
complex and varied. The objective of this analysis was to iden-
tify how various patterns of treatment relate to direct costs.
METHODS: The PharMetrics Integrated Outcomes Database 
of adjudicated medical and pharmaceutical claims for over 3
million patients from 11 U.S. health plans was utilized. 3,648
bipolar patients were identiﬁed based on the following criteria:
two claims with ICD-9-CM diagnosis for bipolar disorder
(296.0, 296.1, 296.4–296.8) that were not accompanied by a
unipolar depression claim on the same day, age between 10 and
64, and 1 year of continuous eligibility prior to and following
the initial bipolar diagnosis. Thirteen months of data were ana-
lyzed (1 month pre diagnosis, 12 months post diagnosis).
RESULTS: Eighty-two percent of patients (2992) were treated
with medication. For drug treated patients, on average, the total
cost over the 13-month period is $12,416 per patient. Of this
amount, 65% of the costs ($8018) are bipolar-related; with a 
5 :1 ratio of medical services related costs ($6,691) to medica-
tion costs ($1327). Patients initiating on poly-pharmacy incur
higher total bipolar costs ($10,137) than their cohorts who ini-
tiated on mono therapy ($6,683). As expected, as the number of
drugs used increases, total bipolar costs steadily rise with the
average being $3,883 for one drug, $11,419 for four drugs and
$19,040 for 9 drugs. Additionally, as the number of treatment
regimes per patient increases, so do costs. Total bipolar costs for
patients having only one treatment regime average $3,528,
whereas patients experiencing 3 switches (four regimes) average
$12,553. CONCLUSION: Many factors are related to the cost
of treating bipolar patients. Further investigation needs to be
conducted in order to understand which of these factors might
be cost containment opportunities.
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OBJECTIVE: To assess cost consequences associated with dif-
ferent initial therapies and comorbidity factors for patients with
bipolar disorders in a managed care Medicaid population.
METHODS: Using a multi-state claims database from January
1998 to December 2002, 3676 newly treated bipolar patients
were selected if they had not been treated during the preceding
3-months and had a minimum 3-month follow-up period and at
least two bipolar-related diagnoses and prescriptions. The cost
consequence measured by total charge was further divided into
bipolar-related and or not. Using Poisson regression analysis,
costs were regressed on patient’s age, gender, initial therapy,
major psychiatric disorders, and general clinical comorbidities.
RESULTS: The cohort patients had 87.9% bipolar I, 66.6%
female, average age of 27.2 (SD 13.8). Initial therapy involved
atypical antipsychotics monotherapy (12.4%), lithium/anticon-
vulsants (22.6%), combination of atypical and lithium or anti-
convulsant (31.1%), other combination of typical antipsychotics
and antidepressants (33.9%). Bipolar-related cost was relatively
stable overtime with monthly average of $384 (SD 845), and sig-
niﬁcantly associated with bipolar I (Odds Ratio = 1.30; 95% CI
1.056–1.63), major depression (OR 1.74; 1.51–2.02), substance
abuse (OR 1.67; 1.44–1.94), anxiety disorder (OR 1.18;
1.04–1.34), impulse control disorder (OR 1.40; 1.17–1.67), per-
sonality disorder (OR 1.46; 1.20–1.76), eating disorder (OR
1.93; 1.28–2.76). The total health care cost (bipolar and non-
